[ad_1]
SOURCES:
Alexander Truong, MD, pulmonologist, assistant professor, Emory College Faculty of Drugs, Atlanta.
Alexander Charney, MD, PhD, lead principal investigator, RECOVER grownup cohort, affiliate professor of psychiatry, genetics and genomic sciences, neuroscience, and neurosurgery, Icahn Faculty of Drugs at Mount Sinai, New York.
Michael Peluso, MD, assistant professor of drugs, infectious illnesses physician, College of California, San Francisco.
Rainu Kaushal, MD, senior affiliate dean for medical analysis, Weill Cornell Drugs, New York.
The Lancet eClinicalMedicine: “Characterizing lengthy COVID in a world cohort: 7 months of signs and their affect.”
Nature Evaluations Microbiology: “Lengthy COVID: main findings, mechanisms and suggestions.”
Immunity, Irritation and Illness: “COVID-19 related EBV reactivation and results of ganciclovir remedy.”
Scientific Infectious Ailments: “Persistent Circulating Extreme Acute Respiratory Syndrome Coronavirus 2 Spike Is Related With Submit-acute Coronavirus Illness 2019 Sequelae.”
Cell Experiences Drugs: “The IL-1β, IL-6, and TNF cytokine triad is related to post-acute sequelae of COVID-19.”
Nature Drugs: “Knowledge-driven identification of post-acute SARS-CoV-2 an infection subphenotypes,” “Molecular states throughout acute COVID-19 reveal distinct etiologies of long-term sequelae.”
Nature Immunology: “Immunological dysfunction persists for 8 months following preliminary mild-to-moderate SARS-CoV-2 an infection.”
Science Translational Drugs: “Persistent put up–COVID-19 odor loss is related to immune cell infiltration and altered gene expression in olfactory epithelium.”
European Respiratory Journal: “Circulating anti-nuclear autoantibodies in COVID-19 survivors predict lengthy COVID signs.”
Journal of Medical Virology: “Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute part COVID-19 sufferers.”
Johns Hopkins Drugs: “What are widespread signs of autoimmune illness?”
[ad_2]
